Of note, a diagnostic c-MYC immunohistochemical staining has been developed for hematological cancers (45), and this could potentially support the use of c-MYC in future clinical studies of TAK-243 or newer UBA1 inhibitors in TNBC. The gene discussed is UBA1; the disease is hematopoietic and lymphoid cell neoplasm.